Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 Oct 26;5(11):e580. doi: 10.1016/S2468-2667(20)30228-0

Frailty and mortality in patients with COVID-19

Jai N Darvall a,b, Rinaldo Bellomo a,b,c,d, Paul J Young e, Kenneth Rockwood f, David Pilcher c,g,h
PMCID: PMC7588213  PMID: 33120041

We read with interest the study by Jonathan Hewitt and colleagues,1 investigating the association of frailty with mortality in 1564 patients diagnosed with COVID-19. We are interested in how treatment varied between patients in different frailty categories. Although the outcomes were adjusted for baseline patient factors, including age and comorbidities, we note that neither illness severity nor important process measures after admission to hospital, such as intensive care unit admission or mechanical ventilation, were reported. Without these data, it is hard to say to what degree frailty per se is intrinsically associated with increased mortality in COVID-19, or whether the reported mortality is perhaps related to the combination of a more severe illness and less intensive treatment type offered to patients with advanced frailty, consistent with the guidance from the National Institute for Health and Care Excellence and earlier work, which show greater treatment limitations in older, frail cohorts.2, 3

The latest intensive care national audit & research centre report (published on June 19, 2020), incorporating 9949 critically ill UK patients with COVID-19, reports a median patient age of 60 years (vs 74 years in Hewitt and colleagues' cohort), with 90% of patients fully independent (“able to live without assistance in daily activities”) before hospitalisation.4 These numbers compare with 40% of this study's cohort being classified as having a Clinical Frailty Scale score of 6 or more (at least moderately frail); by definition requiring considerable assistance with daily activities.5 Hewitt and colleagues'1 study cohort, then, is not typical of the COVID-19 population being managed in UK intensive care units. Without more detail on how patients in this study were treated, and what effect this had on mortality, we are concerned that the statement “these findings support the use of frailty as a trigger for specialist resource allocation” is not supported by the data presented.

Acknowledgments

KR reports personal fees from Clinical Cardio Day-Cape Breton University, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Jackson Lab (Bar Harbor, MA, USA), MouseAge (Rome, Italy), Lundbeck, Frontemporal Dementia Study Group, and SunLife Insurance (Japan); and is the President and Chief Science Officer of DGI Clinical, which in the last 5 years has contracts with pharmaceutical and device manufacturers (Baxter, Baxalta, Shire, Hollister, Nutricia, Roche, and Otsuka) on individualised outcome measurement; attended an advisory board meeting with Lundbeck in 2017; is the Associate Director of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian Institutes of Health Research, and with additional funding from the Alzheimer Society of Canada and several other charities, as well as, in its first phase (2013-2018), from Pfizer Canada and Sanofi Canada; receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, and research support from the Canadian Institutes of Health Research, the QEII Health Science Centre Foundation, the Capital Health Research Fund and the Fountain Family Innovation Fund of the QEII Health Science Centre Foundation. All other authors declare no competing interests.

References


Articles from The Lancet. Public Health are provided here courtesy of Elsevier

RESOURCES